Irritable Bowel Syndrome (IBS) Treatment With H1-receptor Antagonists
Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
Purpose:
To evaluate the efficiency of Irritable Bowel Syndrome (IBS) patients treatment with the
H1-receptor antagonist ebastine.
Design:
Double blind randomized placebo controlled trial. IBS patients receive a 12-weeks treatment
with ebastine 20mg once daily or placebo (1:1 randomization).
End points:
End point is the effect of treatment on clinical symptoms and visceral hypersensitivity which
will be evaluated with a barostat test.